Target intelligence / Profile preview

MicroRNA 505 (miR-505)

Target
miR-505
Molecular classification
MicroRNA, Non-coding RNA, miRNA
01

Overview

MicroRNA 505 (miR-505) is a small, non-coding RNA belonging to the microRNA family, involved in the post-transcriptional regulation of gene expression by binding to target mRNAs and inhibiting their translation or promoting their degradation. It is frequently downregulated in multiple cancer types, where it functions as a tumor suppressor. miR-505 inhibits cancer cell proliferation, migration, invasion, and metabolic reprogramming by targeting several oncogenes such as IGF-1R, HK2, CDK5, and others. Restoring miR-505 expression in tumor models suppresses malignancy and sensitizes cells to chemotherapy. Low miR-505 levels are associated with advanced disease stage, metastasis, and worse overall survival, highlighting its relevance as a prognostic marker and potential therapeutic target.

Other names
hsa-miR-505MIR505MIRN505hsa-mir-505mir-505
02

Mechanism of action

Tumor suppression by direct targeting and inhibition of oncogenes (e.g., IGF-1R, HK2, HMGB1, CDK5, TGF-α, FZD4, WNT7B, MAP3K3, NRCAM, RUNX2); Interfering with signaling pathways involved in cell proliferation, metabolism, and survival

03

Biological functions

Post-transcriptional regulation of gene expressionRegulation of cell proliferationApoptosisInhibition of cell migration and invasionRegulation of epithelial–mesenchymal transition (EMT)Modulation of glycolysis/metabolism
04

Disease associations

Cancer (notably hepatocellular carcinoma, pancreatic cancer, cervical cancer, osteosarcoma, endometrial cancer, and others)Endometrial diseaseDystonia 3, torsion (X-linked)
05

Safety considerations

Therapeutic strategies targeting miR-505 would need to consider off-target effects on global gene regulation; as a microRNA, targeting could have broad cellular impacts. Specific safety concerns are not well described in current literature
06

Interacting drugs

Doxorubicin
07

Biomarkers

Low miR-505 expression as a prognostic biomarker in several cancers, correlating with poor prognosis and aggressive clinicopathological features

Beyond the preview

Go deeper on MicroRNA 505 (miR-505).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 505 (miR-505).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call